PALB2 mutation

PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYj5RW #NCT05169437 #PrecisionMedicine https://t.co/SlEmF3meSl (@mtmdphd)

#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/OEtmH9mySq @DanaFarber @LantheusNews @Progenics (@urotoday)

Live from @ASCO @KReissMD explains a new #clinicaltrial currently enrolling patients with early-stage #pancreaticcancer with BRCA1, BRCA2, or PALB2 mutations. #ASCO23 @PennCancer @BasserBRCA @theNCI @eaonc Learn more:https://t.co/WxpoDeFgUs (@PennMDForum)

#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/OEtmH9mySq @DanaFarber @LantheusNews @Progenics (@urotoday)

#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/OEtmH9mySq @DanaFarber @LantheusNews @Progenics (@urotoday)

H.Pylori infection significantly increases the risk of gastric cancer in persons with inherited mutations in BRCA2, BRCA1 , ATM, and PALB2 compared to non-carriers. The good news is that eradicating H.Pylori is relatively easy and may help mitigate risk. https://t.co/weMai50Ja1 (@Ecastromarcos)

PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYiy2o #NCT05169437 #PrecisionMedicine https://t.co/SlEmF3lH2N (@mtmdphd)

#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/OEtmH9mySq @DanaFarber @LantheusNews @Progenics (@urotoday)

Neoadjuvant Olaparib WINDOW Trial in Newly diagnosed BRCA mutant high grade serous ovarian cancer (including RAD51C, PALB2): 53% PR, 46% SD, 0% PD, 1 patient with pathological CR, 85% no gross residual dz, 14% < 1cm residual. #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress (@ChristiKimMD)

After neoadjuvant talazoparib results in BRCAm BC (Litton J.K. 2017), neoadjuvant olaparib in #ovariancancer (with mutation in BRCA1/2, RAD51C/D, or PALB2) by @ShannonWestin shows outstanding surgical outcomes after only 2 cycles of olaparib, even in Stage IV pts #SGOMTG #SGO2023 (@AllegraRollo)

#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/OEtmH9mySq @DanaFarber @LantheusNews @Progenics (@urotoday)

Prostate cancer(mCRPC)with a somatic PALB2 mutation--> Excellent PSA/Radiological response with 4th line Cabazitaxel/Carboplatin 🎯 @AmitJos98615230 @tompowles1 @drvineetgovinda @rakesh_boya @rajitrattan @DrVijayPatil11 @myESMO @JCOOP_ASCO @OncBrothers (@shikharkumar89)

Learn the link between BRCA1, BRCA2, PALB2 gene mutations and pancreatic cancer. #cancer #genetics #pancreaticcancer @TimothyJBrownMD @KReissMD @PennCancer #ASCO22 Watch video here: https://t.co/OtTUYMilnC.?channelName=AnnualCancerMeeting#gsc.tab=0 (@oncologytube)

PAVO: A Pan-Tumor PALB2 PARP Inhibitor Study -- A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations - @TempusLabs @GSK https://t.co/L3jMTYj5RW #NCT05169437 #PrecisionMedicine https://t.co/rvCxMrCr2F (@mtmdphd)

#APOLLO Clinical trial #BRCA #PALB2 #PancreaticCancer @KReissMD #olaparib olaparib in pancreatic cancer with a BRCA1/2 or PALB2 mutation [Video] – Cancer Research and Information Vlog | GiveTaxFree https://t.co/F1pYrg8A3m (@perilonthesea)

👏Reversion mutation uncommon in #cfDNA but indicates ⬇️ poorer outcome in pts with 🧬BRCA PALB2 mutant (HRD) #PancreaticCancer KRAS detection also show ⬇️ outcome on PARPi rucaparib maintenance by our colleagues @KReissMD & 💫Tim Brown at UPenn powerhouse for PDAC 🔬 #GI23 @ASCO (@CentralParkWMD)

Risk of contralateral BC among #BRCA #CHEK2 #ATM and #PALB2 mut carriers. 👉 In post-meno: 3.7% non-carriers, 4.3% CHECK2 and 4.6% ATM. ☝️Precious data for surgery personalization! #SABCS22 @SABCSSanAntonio (@angela_toss)

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) ⁦@AnnSurgOncol⁩ ⁦@McMastersKelly⁩ ⁦@IHPBA⁩ ⁦@Shrikhande_SV⁩ https://t.co/c8mJMG2cJX (@SyedAAhmad5)

Actually, that is definitely not true - or just oversimplified. BRCA1/2/PALB2 mutations are definitely drivers in a 5-8% of pancreatic cancers, and targeting those patients with a PARP inhibitor can be highly effective. The key is how to use these drugs in the optimal way! (@MPishvaian)

EA2192/APOLLO is treating patients with #pancreatic cancer that has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation. Learn more about this #clinicaltrial during #PancreaticCancer Awareness Month: https://t.co/oBs1EbhYmU #PANCaware #pancsm cc: @KReissMD (@eaonc)

OT3-11-02 Thursday @SABCSSanAntonio SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL Presenter: Dr. J. Balmaña (@prat_aleix)

Research led by @utswcancer's @joshuagruber finds that talazoparib shrank tumors of breast cancer patients with mutations in the PALB2 gene. Nice work, Josh https://t.co/1bl1fVqjOP (@CarlosArteagaMD)

Great talk by @EileenMOReilly at @pan_association and extra thanks for the EA2192/APOLLO shout out. Please remember this trial for your patients with resected #pdac and #brca or PALB2 mutations! @eaonc @NCICancerTrials @anup_kasi (@KReissMD)

A new study by Komen researchers @joshuagruber @anosheha & Komen Scholar @melindatelli identifies patients with advanced #HER2- #breastcancer and inherited PALB2 mutations are uniquely sensitive to PARP inhibitor drugs. Read the full report here: https://t.co/bK9jbEMYXp (@SusanGKomen)

This study identifies breast cancer patients with inherited PALB2 mutations as uniquely sensitive to Parp inhibitors. Our trial design excluded BRCA1/2 mutations. (@joshuagruber)

Wonderful presentation on #moderatepenetrance #geneticmutations by @claudine_isaacs Of note, consider annual MRI for CHEK2 and ATM carriers starting at age 30-35 Data on PALB2 indicates it may be a high risk mutation, with breast cancer RR = 7 @LurieCancer #LSBC22 (@ellieprouss)

I think 'actionable' is being used here in the germline sense. An incidental PALB2 mut on NGS of a NSCLC may suggest an underlying germline variant - if confirmed it could be actionable for that patient & family's cancer risk. More from @myESMO here: https://t.co/cmflTnSdyw (@geoff_oxnard)

I would encourage all to enroll patients in @eaonc EA2192 #APOLLO trial led by @KReissMD to examine the role of maintenance #PARP inhibitor following (neo)adjuvant therapy in resected mutated #BRCA or #PALB2 #PDAC @PanCAN @NatPancFdn @IHPBA https://t.co/URGZYm80JO (@FlavioRochaMD)

Thank you for the link. In your opinion, do you think that a tnbc patient with a PALB2 mutation, that has residual after neoadjuvant chemo, should use Olaparib or Capecitabine? (@RyanMarvinArt)

Optimal management for pts w BRCA/PALB2-mutated pancreas cancer after progression on PARPi maintenance remains under debate. Particularly, it is unknown if platinum chemotherapies retain activity. #ASCO22 (@TimothyJBrownMD)

One important lesson from the #AACR22 session on #PancreaticCancer where Dr. @EileenMOReilly stressed the importance of somatic & germline sequencing, especially in young onset PC (<50Y). The PALB2 mutation has been pivotal to the welcome response & long term survival seen here. (@Aiims1742)

How about that! Rucaparib is now in the @NCCN guidelines for pancreas cancer as a result of @KReissMD phase 2 trial showing potential benefit in pts with BRCA/PALB2 mutations. @mmwatt02 @PennCancer @BasserBRCA https://t.co/pdcUQ4bjei (@TimothyJBrownMD)

New research from @MarkRobsonMD in @JAMAOnc suggests new breast cancer screening guidelines for women with ATM, CHEK2, and PALB2 mutations. This could reduce the risk of death by over 50% for women with those mutations. https://t.co/9kYamzB3ob (@RoxanneTaylor)

New research from @MarkRobsonMD in @JAMAOnc suggests new breast cancer screening guidelines for women with ATM, CHEK2, and PALB2 mutations. This could reduce the risk of death by over 50% for women with those mutations. https://t.co/7m0M6f33Dc (@AnnikAllen)

New research from @MarkRobsonMD in @JAMAOnc suggests new breast cancer screening guidelines for women with ATM, CHEK2, and PALB2 mutations. This could reduce the risk of death by over 50% for women with those mutations. https://t.co/b9CUtWwXFs (@RWilliams_MSK)

For women w germline pathogenic ATM, CHEK2, PALB2, mutations, comparative modeling suggests that "screening MRI starting at age 30 to 35 years may substantially reduce breast cancer mortality..." #bcsm @OncoAlert @JAMAOnc @MarkRobsonMD @AllisonKurian https://t.co/FlJexj8r6u (@StoverLab)

For Less Familiar Gene Mutations #ATM, #CHEK2, and #PALB2 linked to #breastcancer: Research Aims to Create Screening Guidelines with @MarkRobsonMD @sloan_kettering #bcsm #hereditarycancer #cancerresearch #genetics #womenshealth https://t.co/9bx7vVndxy (@LguzzardiM)

🚨#BREAKING: New research from @MarkRobsonMD in @JAMAOnc suggests new #BreastCancer screening guidelines for women with #ATM, #CHEK2, and #PALB2 mutations. This could reduce the risk of death by over 50% for women with those mutations. Read more 👇 https://t.co/G6OEDkPMr1 (@sloan_kettering)

FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations https://t.co/GeGNztzN7t #bcsm #gyncsm (@aftimosp)

In the report, all three sisters had an identical germline PALB2 mutation, which appears to track with #PancreaticCancer occurrence / risk & is associated with response to platinum & PARPinh. @pashtoonkasi @EileenMOReilly @drallysonocean @MPishvaian @OncoAlert @precisionpanc (@Aiims1742)

These patients with a history of #breastcancer having pathogenic #BRCA2 or #PALB2 mutations, for example, should all be automatically offered #pancreaticcancer surveillance despite absence of family history. HBOC syndromes need to include all gender neutral #hereditarycancer(s) (@LguzzardiM)

#TumorBoardTuesday That is a great observation @anup_kasi Patients with BRCA1/2/PALB2-mutated breast cancer have to be made aware of, and be screened for #PancreaticCancer #PancreaticCancerAwarenessMonth (@MPishvaian)